588 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Strive Asset Management LLC

Strive Asset Management LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 588 shares of the biopharmaceutical company's stock, valued at approximately $419,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Park Avenue Securities LLC grew its stake in Regeneron Pharmaceuticals by 6.9% in the fourth quarter. Park Avenue Securities LLC now owns 2,019 shares of the biopharmaceutical company's stock valued at $1,438,000 after purchasing an additional 130 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 3,106 shares of the biopharmaceutical company's stock valued at $2,212,000 after buying an additional 99 shares in the last quarter. Fermata Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $207,000. Merit Financial Group LLC grew its position in shares of Regeneron Pharmaceuticals by 8.9% in the 4th quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company's stock worth $618,000 after buying an additional 71 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management grew its position in shares of Regeneron Pharmaceuticals by 154.8% in the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,147 shares of the biopharmaceutical company's stock worth $2,242,000 after buying an additional 1,912 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $594.32 on Friday. The stock has a market cap of $64.17 billion, a P/E ratio of 15.53, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The stock has a 50 day moving average of $599.96 and a two-hundred day moving average of $682.98. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the company earned $9.55 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Wall Street Analyst Weigh In

Several analysts have recently commented on REGN shares. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Guggenheim decreased their price target on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. TD Cowen dropped their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.